Positive macroeconomic news, including a monthly surge in US consumer spending, broke the market out of the doldrums that had dominated the trading week so far. Indexes are up broadly, with most sectors up at the time of this writing.

Our Top Performer today is a long play, in keeping with the overall market momentum. But today’s top-gainer exhibited price growth that’s astonishing even within the hallowed halls of our biggest one-day gainers of the year.

Arcturus Therapeutics Ltd  (ARCT): gains over 400% on merger news.

Pharmaceutical news continues to be one of the most frequent sources of explosive same day profits for NQ users. Clinical trial data can profoundly change the market’s valuation of a security almost instantaneously. In the same vein, a major pharma acquisition can provide compelling evidence of the commercial viability of a given pharma firm’s product.

Today, Arcturus Therapeutics, a developer of RNA-based medicines, announced that it has completed a previously announced merger with Alcobra, another drug developer. The new combined entity has over 50 million in cash on hand, coupled with multiple externally funded product pipelines

Additionally, ARCT announced new strategic agreements with major industry players Johnson & Johnson and Synthetic Genomics. The new combined entity is expected to pursue a wide range of RNA-related treatment research and development.

Based in San Diego, the new firm will operate under the Arcturus name and begin trading on the NASDAQ.

Investors piled into the stock on truly massive volume on the news, driving the stock up as far as 430% before consolidating at its current price, just over 400%. Investors are hungry for safe sources of long-term earnings in a highly valued market, and viable pharmaceutical products are one of the best bets for sustained revenue earning power—if you can find the associated stock at a good value.

Diverse Plays, Great Profits: All in a single news day.

Keep checking our blog for daily updates on lucrative new-based stock plays, analyst actions, and more!

We analyze news events ranging from clinical trials in the pharmaceutical industry to routine earnings releases to major geopolitical shakeups.

Or, if you’re ready to move beyond the blog and experience the power of hedge-fund caliber news analysis in a package that’s accessible to small investors, click here to sign up for a free training today. You’ll see how easy to use our platform really is—and how many profitable trades it can unlock

A powerful news analytics platform like NewsQuantified not only makes it easy to track the news, but to quickly compare news events with key financial information. We make it simple to find strong, diverse plays in any market environment.

How are you using the news to earn market-beating profits? How would you use the news if you had access to a real-time platform like NewsQuantified?  Let us know in the comments below.

Leave a comment